More MS Academy Medication Projects
Streamlining the local Multiple Sclerosis Disease Modifying Therapy MDT
By Mark Maskery, ST4 Neurology, Royal Preston Hospital
Clinical impact of Ocrelizumab dosing delays and their association with CD-19+ B-cell repletion during the COVID-19 pandemic
By Dr Nitin Sahi, Neurology SpR, University Hospitals of North Midlands NHS Trust
Highly active disease-modifying therapy initiation patterns in multiple sclerosis patients during the Covid19 pandemic: the Royal Free London NHS Trust experience
By Dr Charmaine Yam, Neurology Clinical Fellow, Royal Free London NHS Foundation Trust
Encouraging excellence, developing leaders, inspiring change
MS Academy was established six years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.